1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Claritas Pharmaceuticals, Inc.

Claritas Pharmaceuticals, Inc.

CLAZF
Claritas Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
3,659.00Market Cap
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
TTM
Revenue per Share
19.26
0.11
8.67
14.77
8.68
4.37
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1,111.14
-245.99
-175.88
-209.42
-227.04
-183.89
-0.47
-3.07
-7.86
-5.13
0.71
-0.95
0.16
-0.15
Free Cash Flow per Basic Share
-2,400.93
-353.49
-270.39
-237.78
-93.64
-89.49
-13.63
-2.47
-1.11
-0.9
-0.5
-0.29
-0.01
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,410.06
-561.47
-376.99
-376.32
-590.56
-774.45
-774.93
-3.33
-8.89
-2.51
-3.89
-2.64
-2.06
-1.84
Tangible Book Value per Share
2,732.71
1,605.95
743.14
431.27
194.62
-11.18
-11.38
0.96
1.98
-11.78
-5.02
-1.27
-0.3
0.1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
6
10
22
27
32
Sales/Revenue/Turnover
- -
- -
- -
2
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-4,881.58
-183,355.38
-1,757.17
-502.25
-656.39
-1,374.07
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-4
-8
-22
-25
-20
- -
-1
-12
-32
7
-21
4
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,768.18
-229,180.91
-2,028.07
-1,418.05
-2,616.47
-4,211.7
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-3
3
20
16
- -
-1
-1
- -
3
- -
-7
-6
-6
3
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
- -
- -
- -
- -
Total Equity
9
25
35
45
21
-1
-1
- -
3
-12
10
-3
2
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.73
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'21
Jun'21
Sep'21
ST Debt
- -
1
1
LT Borrowings
- -
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
35
35
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'21
Jun'21
Sep'21
Total Current Assets
1
11
11
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
8
8
Payables & Accruals
6
1
1
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-66.2%
-80.07%
-143.85%
Free Cash Flow
13.66%
42.02%
-95.23%
Net Income, GAAP
295.31%
50.24%
-119.85%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-0.42
-0.24
-0.04
- -
-0.95
2020
0.53
-0.33
-0.02
- -
0.16
2021
-0.08
-0.06
0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Robert Farrell
Full Time Employees
3
Sector
Healthcare
Industry
Biotechnology
Address
4040 Civic Center Drive San Rafael CA United States of America 94903
IPO Date
Apr 12, 2016
Website
claritaspharma.com
Similar Companies
Moderna, Inc. (0QF.F)
3B BlackBio Dx Ltd (3BBLACKBIO.BO)
Immuno-Biological Laboratories Co., Ltd. (4570.T)
PHAXIAM Therapeutics S.A. (PHXM.PA)
Cannassure Therapeutics Ltd (CSURE.TA)
BioAtla, Inc. (BCAB)
Business
Claritas Pharmaceuticals, Inc. (CLAZF) is a clinical-stage specialty pharmaceutical company that develops and commercializes therapies addressing unmet medical needs in areas including pulmonary arterial hypertension and pain management; its lead product candidate, R-107, is a small-molecule therapeutic in Phase 1 clinical trials targeting pulmonary arterial hypertension with plans for a subsequent Phase 2a study, while CLA-1816 advances in preclinical development as an alpha3 glycine receptor agonist for pain relief. Founded in 2014 and headquartered at 4040 Civic Center Drive, Suite 200, San Rafael, California, the company, formerly known as Kalytera Therapeutics, Inc., rebranded to Claritas Pharmaceuticals, Inc. in April 2021 and primarily operates in North America with clinical activities extending to Australia. Recent developments include approval from OTC Markets to uplist its common shares to the OTCQB Venture Market for enhanced trading visibility and a $5 million equity financing facility secured with Alumina Partners (Ontario) Ltd. to support ongoing operations and pipeline advancement.